University Of Tartu
- Address
- L. Puusepa Tn 8, 50406 Tartu, Estonia
Cardiovascular Research
The Department of Cardiology at University of Tartu focuses on cardiovascular diseases, especially acute myocardial infarction (AMI). Ongoing trials evaluate self‑administered treatments to improve early symptom management and lower the risk of recurrent heart attacks.
- Self‑administered thrombin receptor antagonists
- Rapid response protocols for AMI
- Risk stratification in recurrent cardiac events
The site conducts two investigator‑led studies with commercial collaboration, aiming to bring faster, patient‑controlled therapies to the clinic.
Oncology & Immunotherapy
Research at University of Tartu also targets neoplasms, concentrating on unresectable or metastatic melanoma. Current investigations compare novel biologic agents to established checkpoint inhibitors to enhance treatment effectiveness for patients who have not received prior systemic therapy.
- Bispecific antibody development
- Checkpoint inhibitor combination strategies
- Biomarker‑driven melanoma therapies
Supported by a commercial partner, the two trials aim to expand therapeutic options and improve survival outcomes in advanced melanoma.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Viatris Innovation GmbH1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Tartu
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Subcutaneous Selatogrel in Preventing Recurrent Acute Myocardial Infarction in Post-AMI Patients | Viatris Innovation GmbH | Phase III | Recruiting | Jan 2022 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Nivolumab | 1 | Unknown | 2024-01-26 | 2024-01-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.